Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model.

Clin Med Insights Oncol · 2011 · PMC3201113 · PMID 22084620

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally significantP = 0.05actually significant

The clinically equivalent medium-dose BCG treatment demonstrated a marginally significant anti-tumor and survival benefit ( P = 0.05, Mantel-Cox test) over saline.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.